About
Technology
Issues
FAQ
Links
Official Page
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.